Search results
Results from the WOW.Com Content Network
SSRI antidepressants all have the same mechanism of action and are at least 10-fold more selective for 5-HT re-uptake inhibition than for NE re-uptake inhibition. However, despite the sharing of the same mechanism of action, SSRIs differ in their potency and selectivity in inhibiting 5-HT re-uptake and many of them have important effects on ...
Critics of antidepressants maintain that the superiority of antidepressants over placebo is the result of systemic flaws in clinical trials and the research literature. [ 95 ] [ 87 ] Trials conducted with industry involvement tend to produce more favorable results, and accordingly many of the trials included in meta-analyses are at high risk of ...
The pharmacology of antidepressants is not entirely clear.. The earliest and probably most widely accepted scientific theory of antidepressant action is the monoamine hypothesis (which can be traced back to the 1950s), which states that depression is due to an imbalance (most often a deficiency) of the monoamine neurotransmitters (namely serotonin, norepinephrine and dopamine). [1]
Tricyclic antidepressants (or TCAs) are a type of antidepressant developed in the 20th century. They’re among some of the first prescription medications to be approved by the FDA.
The history of antidepressants. Most antidepressants aim for the same target: the monoamine system. They work by raising levels of one or more of the monoamine neurotransmitters in the brain that ...
Berlin: Georg Reimer [A chronology of events in the history of psychiatry until 1893]. Simon, Bennett (1980). Mind and Madness in Ancient Greece : The Classical Roots of Modern Psychiatry. Ithaca, NY: Cornell University Press. ISBN 9780801408595. Thomas S. Szasz (1977).
Antidepressants are a class of medications used very commonly to treat depression. In fact, nearly 13 percent of people 12 and over in the U.S. used antidepressants in 2017, according to the ...
[6] [11] The 2008 meta-analysis combined 35 clinical trials submitted to the Food and Drug Administration (FDA) before licensing of four newer antidepressants (including the SSRIs paroxetine and fluoxetine, the non-SSRI antidepressant nefazodone, and the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine).